AstraZeneca and AVEO Oncology Enter into an Immuno-Oncology Clinical Collaboration

• AstraZeneca and AVEO collaborates to evaluate safety and efficacy of AstraZeneca’s Imfinzi (durvalumab) + AVEO’s Fotivda (tivozanib) in P-I/II for 1L HCC or liver cancer
• AVEO plans to initiate the onset of P-I trial for the combination therapy in 2019, with equal cost sharing
• Imfinzi (durvalumab) is mAb binds with PD-L1, further blocking its interaction with PD-1 and CD80 and evaluated as monothx or in combination for multiple cancers.  Fotivda (tivozanib) PO is qd VEGF
  receptor tyrosine kinase inhibitor approved for advance RCC in EU

Click here to read full press release/ article | Ref: AVEO Oncology | Image: Pharma Journalist